公开(公告)号：KR20180019223A

公开(公告)日：2018-02-23

申请号：KR20187002033

申请日：2016-06-22

Applicant: SERVIER LAB ,  VERNALIS R&D LTD

Inventor： SZLAVIK ZOLTAN ,  KOTSCHY ANDRAS ,  CHANRION MAIEA ,  DEMARLES DIDIER ,  GENESTE OLIVIER ,  DAVIDSON JAMES EDWARD PAUL ,  MURRAY JAMES BROOKE ,  SIPOS SZABOLCS ,  PACZAL ATTILA ,  BALINT BALAZS

IPC: C07D495/04 ,  A61K31/519 ,  A61P35/00 ,  A61P37/00

CPC classification number: C07D495/04

Abstract: 하기화학식 (I)의화합물.상기식에서, R, R, R, R, R, R, R, R, R, R, A 및 n은설명에정의된바와같다. 암치료에사용하기위한이들을함유하는약제.

Abstract translation: 其中R，R，R，R，R，R，R，R，R，R，A和n如说明书中所定义。 含有它们的药物用于治疗癌症。

公开(公告)号：WO2006082304A3

公开(公告)日：2007-02-15

申请号：PCT/FR2006000206

申请日：2006-01-31

Applicant: SERVIER LAB ,  HYBRIGENICS SA ,  GENESTE OLIVIER ,  HICKMAN JOHN ,  RAIN JEAN-CHRISTOPHE

Inventor： GENESTE OLIVIER ,  HICKMAN JOHN ,  RAIN JEAN-CHRISTOPHE

IPC: C07K14/435 ,  A61K38/17 ,  A61P35/00 ,  C12N15/12 ,  C12N15/63 ,  G01N33/566 ,  G01N33/58 ,  G01N33/68

CPC classification number: C07K14/4747

Abstract: The invention relates to the research and identification of novel peptides which interact with anti-apoptotic members of the family of Bcl-2 proteins by means of the double-hybrid system. More specifically, the invention relates to a method of screening and identifying modulators of the protein interaction between said novel peptides and the anti-apoptotic members of the family of Bcl-2 proteins. The modulators identified on the basis of said method are administered to cancer patients in order to induce apoptotic- and/or autophagic-type programmed cell death.

Abstract translation: 本发明涉及通过双杂交体系与Bcl-2蛋白家族的抗凋亡成员相互作用的新型肽的研究和鉴定。 更具体地，本发明涉及筛选和鉴定所述新肽与Bcl-2蛋白家族的抗凋亡成员之间的蛋白质相互作用的调节剂的方法。 基于所述方法鉴定的调节剂被施用于癌症患者以诱导凋亡和/或自噬型程序性细胞死亡。

公开(公告)号：WO2010049816A3

公开(公告)日：2010-07-15

申请号：PCT/IB2009007458

申请日：2009-10-29

Applicant: SERVIER LAB ,  HYBRIGENICS SA ,  GENESTE OLIVIER ,  HICKMAN JOHN ,  COLLAND FREDERIC ,  DAVIET LAURENT

Inventor： GENESTE OLIVIER ,  HICKMAN JOHN ,  COLLAND FREDERIC ,  DAVIET LAURENT

IPC: C12Q1/37 ,  A61P35/00 ,  G01N33/50

CPC classification number: G01N33/5011 ,  A61K38/00 ,  C12Q1/37

Abstract: Use of a polypeptide selected from the group consisting of USP13, USP26, USP38, USP42 or USP46 as a screening tool for an agent for treating cancer.

Abstract translation: 使用选自USP13，USP26，USP38，USP42或USP46的多肽作为治疗癌症的药物的筛选工具。

公开(公告)号：WO2010007248A3

公开(公告)日：2010-04-08

申请号：PCT/FR2009000855

申请日：2009-07-10

Applicant: SERVIER LAB ,  CASARA PATRICK ,  LE DIGUARHER THIERRY ,  DURAND DIDIER ,  GENESTE OLIVIER ,  HICKMAN JOHN

Inventor： CASARA PATRICK ,  LE DIGUARHER THIERRY ,  DURAND DIDIER ,  GENESTE OLIVIER ,  HICKMAN JOHN

IPC: C07D471/04 ,  A61K31/498 ,  A61K31/4985 ,  A61P35/00 ,  C07D207/20 ,  C07D211/70 ,  C07D213/36 ,  C07D241/04 ,  C07D471/14 ,  C07D487/04

CPC classification number: C07D471/04 ,  C07D487/04

Abstract: Compounds of formula (I) in which: A is a (hetero)aromatic or non-(hetero)aromatic ring containing 5, 6 or 7 ring members, Z1, Z2 and Z3 are, independently of one another, a CH group or a nitrogen atom, with at least one of these three groups being a nitrogen atom, X is an alkylene chain as defined in the description, R2 is an aryl or heteroaryl group, and the R1 group is a group of formula (II) as defined in the description.

Abstract translation: 式（I）化合物，其中：A是含有5,6或7个环成员的（杂）芳族或非（杂）芳族环，Z 1，Z 2和Z 3彼此独立地是CH基团或 氮原子，并且这三个基团中的至少一个是氮原子，X是如说明书中所定义的亚烷基链，R 2是芳基或杂芳基，并且R 1基团是如上定义的式（II）的基团 说明。

公开(公告)号：WO2005014638A3

公开(公告)日：2005-06-09

申请号：PCT/FR2004002081

申请日：2004-08-04

Applicant: SERVIER LAB ,  HYBRIGENICS SA ,  GENESTE OLIVIER ,  HICKMAN JOHN ,  BENNETT RICHARD ,  RAIN JEAN-CHRISTOPHE

Inventor： GENESTE OLIVIER ,  HICKMAN JOHN ,  BENNETT RICHARD ,  RAIN JEAN-CHRISTOPHE

IPC: C07K14/47 ,  C12N15/12 ,  G01N33/50

CPC classification number: C07K14/4747 ,  C07K14/4702

Abstract: The invention relates to the identification of a novel peptide interacting with Bcl-2, Bcl-W and/or Bcl-XL anti-apoptotic proteins and to screening methods for identifying the modulators of said interactions.

Abstract translation: 本发明涉及鉴定与Bcl-2，Bcl-W和/或Bcl-XL抗凋亡蛋白相互作用的新型肽，并涉及鉴定所述相互作用调节剂的筛选方法。

公开(公告)号：MX376028B

公开(公告)日：2025-03-07

申请号：MX2018008808

申请日：2018-07-18

Applicant: SERVIER LAB ,  VERNALIS R&D LTD

Inventor： MARAGNO ANA LETICIA ,  KOTSCHY ANDRÁS ,  PACZAL ATTILA ,  BÁLINT BALÁZS ,  DEMARLES DIDIER ,  CHANRION MAÏA ,  GENESTE OLIVIER ,  SIPOS SZABOLCS ,  SZLÁVIK ZOLTÁN

IPC: C07F9/6561 ,  A61K31/519 ,  A61K31/661 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  C07D495/04

Abstract: Compuestos de fórmula (I): (ver Fórmula) en la que R1, R2, R3, R4, R5, R6 e Y son como se han definido en la descripción. Medicamentos.

公开(公告)号：CA3068096C

公开(公告)日：2022-10-04

申请号：CA3068096

申请日：2018-06-21

Applicant: SERVIER LAB ,  NOVARTIS AG

Inventor： WEI ANDREW ,  MOUJALLED DONIA ,  POMILIO GIOVANNA ,  GENESTE OLIVIER ,  MARAGNO ANA-LETICIA

IPC: A61K31/519 ,  A61K31/5377 ,  A61K31/55 ,  A61K45/06 ,  A61P35/00

Abstract: A combination comprising a Mcl-1 inhibitor and a second anticancer agent, wherein the second anticancer agent is selected from anthracyclines, cytarabine and hypomethylating agents, and compositions and uses thereof.

公开(公告)号：MD4793C1

公开(公告)日：2022-09-30

申请号：MD20160018

申请日：2014-07-22

Applicant: SERVIER LAB ,  VERNALIS R&D LTD

Inventor： DAVIDSON JAMES EDWARD PAUL ,  MURRAY JAMES BROOKE ,  CHEN I-JEN ,  WALMSLEY CLAIRE ,  DODSWORTH MARK ,  MEISSNER JOHANNES W G ,  BROUGH PAUL ,  FEJES IMRE ,  TATAI JANOS ,  NYERGES MIKLOS ,  KOTSCHY ANDRAS ,  SZLAVIK ZOLTAN ,  GENESTE OLIVIER ,  LE TIRAN ARNAUD ,  LE DIGUARHER THIERRY ,  HENLIN JEAN-MICHEL ,  STARCK JÉRÔME-BENOÎT ,  GUILLOUZIC ANNE-FRANÇOISE ,  DE NANTEUIL GUILLAUME

IPC: C07D401/14 ,  A61K31/4709 ,  A61K31/4725 ,  A61P35/00 ,  A61P37/00 ,  C07D401/10 ,  C07D405/14 ,  C07D409/14 ,  C07D471/04

Abstract: Invenţia se referă la compuşi noi de izoindolină sau izochinolină, la un procedeu de obţinere a lor şi la compoziţii farmaceutice care le conţin. Prezenta invenţie se referă, în special, la compuşii cu formula (I):unde substituenţii sunt definiţi în descrierea invenţiei. Compuşii, conform invenţiei, au proprietăţi pro-apoptotice, fapt ce permite utilizarea lor în patologii care implică un defect în apoptoză, cum ar fi, de exemplu, în tratamentul cancerului, bolilor autoimune şi bolilor sistemului imunitar.Revendicări: 35

公开(公告)号：BR112021023229A2

公开(公告)日：2022-05-31

申请号：BR112021023229

申请日：2020-05-19

Applicant: SERVIER LAB ,  NOVARTIS AG

Inventor： ANA LETICIA MARAGNO ,  KOTSCHY ANDRAS ,  YU BING ,  MCNEILL ERIC ,  ROCCHETTI FRANCESCA ,  COLLAND FRÉDÉRIC ,  HENLIN JEAN-MICHEL ,  JOHN WILLIAM BLANKENSHIP ,  JOSEPH ANTHONY D'ALESSIO ,  STARCK JÉRÔME ,  NAKAJIMA KATSUMASA ,  DELACOUR LEA ,  CHANRION MAIA ,  MARK G PALERMO ,  CSEKEI MARTON ,  MATTHEW T BURGER ,  GENESTE OLIVIER ,  DESOS PATRICE ,  ZHANG QIANG ,  SIPOS SZABOLCS ,  KOSTOVA VESELA ,  CHEN ZHUOLIANG ,  PROSZENYÁK ÁGNES

IPC: A61K47/68

Abstract: conjugados anticorpo-fármaco inibidores de mcl-1 e métodos de uso. são revelados conjugados anticorpo anti-cd74-fármaco. os conjugados anticorpo anti-cd74-fármaco compreendem uma porção de fármaco inibidor de mcl-1 e um anticorpo anti-cd74 ou fragmento de ligação ao antígeno deste que se liga a um alvo antigênico, por exemplo, um antígeno expresso em um tumor ou outra célula de câncer. a revelação ainda está relacionada aos métodos e composições para uso no tratamento de cânceres por administração dos conjugados anticorpo-fármaco fornecidos nesse relatório descritivo. conjugados ligante-fármaco que compreendem uma porção de fármaco inibidor de mcl-1 e métodos de sua produção também são revelados.

公开(公告)号：BR112016001333B1

公开(公告)日：2022-03-03

申请号：BR112016001333

申请日：2014-07-22

Applicant: SERVIER LAB ,  VERNALIS R&D LTD

Inventor： ARNAUD LE TIRAN ,  CHRISTOPHER JOHN GRAHAM ,  WALMSLEY CLAIRE ,  MADDOX DANIEL ,  GUILLAUME DE NANTEUIL ,  CHEN I-JEN ,  JAMES BROOKE MURRAY ,  JAMES EDWARD PAUL DAVIDSON ,  HENLIN JEAN-MICHEL ,  STARCK JÉRÔME-BENOÎT ,  GENESTE OLIVIER ,  CASARA PATRICK ,  BEDFORD SIMON ,  RAY STUART ,  THIERRY LE DIGUARHER

IPC: C07D401/10 ,  A61K31/4709 ,  A61P35/00 ,  A61P37/00 ,  C07D401/14 ,  C07D405/14 ,  C07D471/04

Abstract: derivados de indol e pirrol, processos para a produção dos mesmos e composições farmacêuticas contendo os mesmos. (i) a presente invenção refere-se aos compostos de fórmula (i), em que ra, rb, rc, rd, r3, r4, r5, a1, a2, t e w são como definidos na descrição. a invenção também se refere aos fármacos contendo os mesmos.